ExaGrid Reports Record Bookings and Revenue for Q2 2019
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup with data deduplication, today announced record bookings and revenue for the quarter’s end in June 2019. ExaGrid posted the best quarter in its history and is on path to post another record bookings and revenue year.
“This was our best bookings and revenue quarter in the history of the company,” said Bill Andrews, CEO and President of ExaGrid. “We had a record number of six-and-seven-figure new customer deals in the quarter, which is a trend that continues to build as we gain momentum in large organizations globally.”
In addition to record Q2 bookings and revenue, ExaGrid achieved the following:
- ExaGrid is expanding support in Chile, Switzerland, India, Indonesia and other countries. ExaGrid has sales staff all over the world including Argentina, Australia, Benelux, Brazil, Canada, Colombia, Czech Republic, Dubai, France, Germany, Hong Kong, Israel, Italy, Mexico, Nordics, Poland, Singapore, South Africa, South Korea, Spain, Taiwan, Turkey, United Kingdom, United States and many others.
- ExaGrid has built upon its strong strategic alliance partner relationships with Veeam Software, HYCU and Zerto. The expanded relationship with HYCU allows for further penetration into organizations deploying Nutanix with ESXi and AHV.
- Enhanced functionality allowing Commvault deduplication to remain turned on so that appliances behind can further deduplicate Commvault data by an additional 3X, which greatly reduces storage costs. ExaGrid is gaining momentum with Commvault customers.
- Voted Storage Magazine’s “Enterprise Backup Hardware Product of the Year” at its annual awards ceremony Storries XVI.
As the market matures, organizations realize the performance degradation that data deduplication can have on backup unless a solution is intentionally architected to prevent any such impact. All deduplication solutions reduce storage and WAN bandwidth to a degree, but only ExaGrid solves the three inherent compute problems to achieve faster backups, restores, and VM boots by leveraging its unique Landing Zone, Adaptive Deduplication, and scale-out architecture.
“First-generation deduplication solutions can be cost prohibitive for backup storage and are slow for backups, restores, and VM boots, which is why over 80% of ExaGrid’s newly-acquired customers are replacing Dell EMC Data Domain, HPE StoreOnce, and the Veritas NetBackup 5200/5300 series of appliances. We are replacing low cost primary storage disk behind Commvault, as ExaGrid is far less expensive than Cisco 3260, NTAP eSeries, HPE Nimble, Dell, etc. when customers require longer term retention,” Andrews said.
All backup storage vendors reduce storage and bandwidth to varying degrees, but most provide slow ingest rates due to deduplication being performed ‘inline.’ Additionally, other solutions only store deduplicated data, which causes restore speeds and VM boots to be very slow. ExaGrid’s ingest rate is 6X faster than its closest competitor. Unlike the first-generation vendors that only add capacity as data grows, ExaGrid appliances add compute with capacity, ensuring that the backup window remains fixed in length. Only ExaGrid uses a scale-out architecture with a unique loading zone, which holistically addresses all of the scalability and performance challenges of backup storage.
ExaGrid’s turnkey disk-based backup system combines enterprise storage with zone-level data deduplication, delivering a disk-based solution that is far more cost effective than low cost disk. Unlike first-generation inline/scale-up deduplication solutions that were either built into a backup application media server or into a dedicated storage appliance, ExaGrid delivers the backup industry’s only true landing zone and scale-out architecture with data deduplication. Utilizing ExaGrid’s landing zone with adaptive deduplication, typically halves the cost of the first-generation large brand solutions and is 3X the backup performance and 20X the restore/VM boot performance. By using a scale-out architecture, ExaGrid is the only solution that keeps the backup window fixed in length as data grows and eliminates both forklift upgrades and forced product obsolescence.
ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu